Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Medicare and medicaid spending trends for immunomodulators prescribed for dermatologic conditions
By
- AMS
posted
May 13, 2020 02:12 PM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Medicaid and Medicare Part B spending on immunomodulators and biosimilars
- AMS
Added Feb 19, 2021
Blog Entry
Psoriasis drugs in the medicare population: dermatologists’ spending and prescription patterns
- AMS
Added Jan 21, 2021
Blog Entry
Trends in Medicare utilization and reimbursement for wound debridement procedures 2012–2017
- AMS
Added Aug 14, 2020
Blog Entry
Dermatological trends in emergency medicine
- AMS
Added Dec 03, 2020
Blog Entry
Analysis of utilization, cost and prescription trends of mycophenolate mofetil and methotrexate among medicare patients
- AMS
Added Jul 15, 2021
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic